Envestnet Asset Management Inc. Sells 2,809 Shares of Envista Holdings Co. (NYSE:NVST)

Envestnet Asset Management Inc. cut its holdings in shares of Envista Holdings Co. (NYSE:NVST) by 2.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 128,880 shares of the company’s stock after selling 2,809 shares during the period. Envestnet Asset Management Inc. owned about 0.07% of Envista worth $2,486,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Venturi Wealth Management LLC increased its position in Envista by 528.4% during the 4th quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company’s stock worth $38,000 after purchasing an additional 1,638 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Envista by 30.5% during the fourth quarter. GAMMA Investing LLC now owns 2,304 shares of the company’s stock worth $44,000 after buying an additional 538 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. bought a new position in shares of Envista in the 4th quarter valued at $53,000. Mitsubishi UFJ Trust & Banking Corp acquired a new stake in shares of Envista during the 4th quarter valued at $86,000. Finally, KBC Group NV grew its position in Envista by 63.9% during the 4th quarter. KBC Group NV now owns 7,903 shares of the company’s stock worth $152,000 after acquiring an additional 3,082 shares during the last quarter.

Envista Stock Down 0.1 %

Shares of Envista stock opened at $15.96 on Friday. The firm has a market cap of $2.75 billion, a price-to-earnings ratio of -2.46, a PEG ratio of 1.27 and a beta of 1.12. The stock’s 50-day moving average is $17.22 and its 200 day moving average is $19.11. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.04 and a quick ratio of 1.76. Envista Holdings Co. has a one year low of $14.22 and a one year high of $23.00.

Envista (NYSE:NVST) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. Equities research analysts anticipate that Envista Holdings Co. will post 1 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on NVST. Jefferies Financial Group lifted their price target on Envista from $20.00 to $22.00 and gave the company a “hold” rating in a research note on Thursday, January 23rd. Wells Fargo & Company set a $19.00 target price on shares of Envista in a research report on Saturday, March 8th. Needham & Company LLC reissued a “hold” rating on shares of Envista in a report on Thursday, March 6th. JPMorgan Chase & Co. dropped their price target on shares of Envista from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Thursday, March 6th. Finally, UBS Group reduced their price objective on shares of Envista from $23.00 to $21.00 and set a “neutral” rating on the stock in a research note on Monday, March 10th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $19.96.

Envista Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.